Real-world Studies of CDK4/6 Inhibitors

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

NCT06176534 ·Status: RECRUITING ·Phase: PHASE2

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT06791161 ·Status: ENROLLING_BY_INVITATION

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

NCT07130643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

NCT07213206 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

NCT07223476 ·Status: COMPLETED

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

NCT07108595 ·Status: COMPLETED

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

NCT07035353 ·Status: NOT_YET_RECRUITING

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

NCT06996093 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

NCT06722599 ·Status: RECRUITING

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

NCT05809024 ·Status: RECRUITING ·Phase: PHASE4

A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.

NCT07290166 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

NCT05728268 ·Status: RECRUITING ·Phase: PHASE2

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532 ·Status: RECRUITING ·Phase: NA

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

NCT05594082 ·Status: UNKNOWN

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

NCT05577442 ·Status: UNKNOWN ·Phase: PHASE2

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

NCT03439735 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT05871918 ·Status: UNKNOWN ·Phase: PHASE3

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

NCT05633914 ·Status: RECRUITING ·Phase: PHASE2

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

NCT06135194 ·Status: RECRUITING

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

NCT04290793 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

NCT00050167 ·Status: COMPLETED ·Phase: PHASE1

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

NCT04481932 ·Status: RECRUITING ·Phase: PHASE2